Introduction
Various epidemiological studies showed the coexistence of diabetes and hypothyroidism. Researchers have discovered the TSH suppressing role of metformin in diabetic patients undergoing levothyroxine (LT4) treatment and excluded the biological interference of metformin with TSH assay, increased LT4 absorption from gastrointestinal tract or any influence of changes in body weight associated with metformin treatment. It was hypothesized that metformin may enhance the inhibitory modulation of thyroid hormones on central thyroid stimulating hormone secretion [1] . In obese, diabetic patients with primary hypothyroidism on thyroxine replacement treatment, shortterm metformin administration is associated with a significant fall in TSH. [2] This emerging finding might render this drug a useful adjunct to the treatment of patients with thyroid cancer and possible readjustment of LT4 doses and will open up new dimension of metformin use and enrich the field of medicine. [3] In the present study, we aim to observe the impact of metformin on serum TSH levels in hypothyroid patients who are on stable and adequate LT4 and found to have diabetes or prediabetes. We also intend to compare the above mentioned group with hypothyroid patients who are on adequate and stable LT4 replacement therapy without diabetes or prediabetes. Although there are many similar studies published on this research problem, this is the first study from Indian subcontinent population.
as well as inpatient section of medicine and endocrinology department, Medical College and Hospital, Kolkata satisfying the inclusion and exclusion criteria between February 2013 and January 2014. Type 2 diabetes or pre-diabetes adult patients of both sexes who were only on metformin alongwith diet and lifestyle modifications and with diagnosed hypothyroidism on adequate and stable L-T4 replacement therapy were included as cases. The control cohort comprised hypothyroid patients (age and sex matched) receiving adequate and stable supplementation of L-T4 without metformin. Patients with uncontrolled hypothyroidism or who were taking oral hypoglycemic agents (OHA) other than metformin or on insulin or on metformin and other OHA or on any hormonal supplementation or medication affecting thyroid function test like oral contraceptive pill etc. were excluded from the study. Laboratory assessments included fasting blood sugar, two hours post load glucose or Post prandial blood sugar, free T4 and TSH were measured and studied at baseline, at three months, at six months and at one year.
Descriptive statistical analysis was carried out in the present study. Results of continuous measurements were presented as mean ± standard deviation (Min-Max) and results of categorical measurements were presented in Number (%). Significance was assessed at the 5 % level. Unpaired t-test to find significant difference in the baseline and follow-up study parameters namely LT4 and TSH between two groups. Repeated measure ANOVA was used to observe the within group differences for the changes in LT4 and TSH. SAS (Statistical Analysis System) version 9.2 for windows, SAS Institute Inc. Cary, NC, USA and SPSS (Statistical Package for Social Sciences) version 20.0 was used for the analysis of the data and Microsoft word and Excel were used to generate graphs and tables.
Results
The study group has two patients aged <30years,13 patients aged between 31-40years,13 patients aged between 41-50 years, nine patients aged between 51-60 years and three patients aged >60 years. The control group has three patients aged <30years,14 patients aged between 31-40years, nine patients aged between 41-50 years,12 patients aged between 51-60 years and two patients aged >60 years. Both the study group (metformin group) and the control group have 17 (17.5%) male and 33 (82.5%) female subjects. In study group 62.5%patients have BMI in between 18.5 -24.9 (normal ),27.5%patients have BMI in between 25-29.9(pre obese),10%atients have BMI ≥30(obese).In control group 65% patients have BMI in between 18.5 -24.9(normal ), 25% patients have BMI in between 25-29.9(pre obese),10% patients have BMI ≥30(obese). In the study group (metformin group) 60% have goitre and in control group (others) 65% have goitre.
In the study group (case cohort) after three months of on metformin, mean TSH was significantly lower than basal TSH (basal TSH: 4.018 ± 0.7207microUI/ml vs. three months after metformin TSH: 3.72 ± 0.6216 microUI/ml, P < 0.0001). Mean FT4 level changes during metformin administration (basal FT4: 1.344 ± 0.2514 ng/dl, three months after metformin FT4:
1.3405 ± 0.2437ng/dl, p= 0.691, which is non-significant. After six months of on metformin, mean TSH was significantly lower than basal TSH (basal TSH: 4.018±0.7207microUI/ml vs. six months after metformin TSH: 2.966 ± 0.7194microUI/ml; P < 0.0001). Mean FT4 level significantly increases during metformin administration (basal FT4: 1.344 ± 0.2514 ng/dl, six months after metformin FT4: 1.372 ± 0.238ng/dl; p=0.007). After 12 months of on metformin, mean TSH was significantly lower than basal TSH (basal TSH: 4.018±0.7207microUI/ml vs. 12 months after metformin TSH: 1.8788 ± 0.6055microUI/ml; p < 0.0001). Mean FT4 level increases during metformin administration (basal FT4: 1.344 ± 0.2514 ng/dl, 12 months after metformin FT4: 1.3848 ± 0.24305ng/dl; p= 0.001) which is once again strongly significant.
Dissimilarly to the case cohort, in control group after three months, mean TSH changes from basal TSH is non-significant (basal TSH: 2.7493 ±1.3579 microUI/ml versus three months after TSH is 2.7518 ±1.3342microUI/ml, p = 0.917). Mean FT4 level changes is also non-significant (basal FT4: 1.3182 ± 0.3080 ng/dl, three months after FT4 is 1.3288 ± 0.2980 ng/dl, p = 0.241). After six months in control group, mean TSH changes from basal TSH is also non-significant (basal TSH: 2.7493 ± 1.3579 microUI/ ml versus six months after TSH: 2.7250 ± 1.3266 microUI/ml, p = 0.358). (Figure 1 ) At six months, mean FT4 level changes is again non-significant in the control cohort (basal FT4: 1.3182 ± 0.3080 ng/dl, six months after FT4 is 1.327 ± 0.2894 ng/dl, p = 0.324). ). (Figure 2 ) After 12 months in control group , mean TSH 
Discussion
Recently, researchers have observed the TSH lowering effect of metformin in patients with diabetes mellitus who are undergoing LT4 treatment and also significant reduction of TSH levels in euthyroid patients with higher baseline TSH levels independently from presence of thyroid peroxidase antibody (TPOAb) 4 . Metformin acts primarily by suppressing hepatic gluconeogenesis via activation of AMPK, a prerequisite for the drug's inhibitory effect at the hepatic level. Metformin is not metabolized but is transported by the organic cation transporters (OCT), OCT1 and OCT2. 5 Interestingly, metformin has the opposite effects on hypothalamic AMPK, inhibiting activity of the enzyme. 6 Although to our knowledge, no studies are available on the regulation of AMPK sub-forms, a1 and a2, in the hypothalamus, these metformin effects on hypothalamic AMPK activity will counteract T3 effects at the hypothalamic level. 7 
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Copyright: © 2016 Sinha, et al. therefore represents a direct target for dual regulation involved in the hypothalamic partitioning of energy homeostasis. In rat experiments, metformin has recently been shown to cross the blood-brain barrier and its concentrations in the hypothalamus match the levels in plasma. 9 Interestingly, metformin levels in the pituitary gland are substantially increased. 9 This may fit with recent findings in a still very small group of patients, suggesting that metformin suppresses pituitary TSH secretion. Metformin treatment has a TSH-lowering effect in hypothyroid patients with PCOS, both treated with L-thyroxine and untreated 1 . Thereby re-evaluation of thyroid function within six-twelve months after starting metformin seems necessary with concomitant hypothyroidism. Treatment with metformin is associated with a significant reduction in the serum levels of TSH in diabetic and pre diabetic patients with primary hypothyroidism receiving LT4 replacement therapy.
Several hypotheses are unable to clarify the association of metformin treatment with the decline in TSH levels even today. The possibility of metformin induced increase of thyroxine absorption from the GI tract is not likely because TSH values also declined in subjects who did not receive thyroxine as shown by other studies. It has been demonstrated that metformin crosses the blood-brain barrier and a central mechanism of TSH inhibition could thus be an attractive explanation. 9 Even though it activates AMPK in the periphery, metformin suppresses AMPK activity in the hypothalamus and possibly counteracts hypothalamic T3 action on TSH secretion. 10 There is also evidence that metformin treatment increases hypothalamic dopaminergic tone in association with improved insulin sensitivity.
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Other hypotheses include changes in the affinity of TH receptors, TH binding, bioavailability and metabolism, induced constitutive activation of the TSH receptor, and interference with the TSH assay. Additionally, it cannot be excluded that elevated TSH values may not necessarily reflect hypothyroidism, but could represent recovery from a nonthyroidal illness, mild resistance to TH, or obesity, as is the case in many patients with DM receiving metformin. 8 Additionally, metformin treatment resulted in a significant decrease in the nodular size (30-55%) in insulin-resistant patients with thyroid nodules, possibly through its action on the insulin signalling pathway. 12 The promising role of metformin as adjuvant therapy in the management of thyroid cancer, especially in diabetic patients is seen through various studies. Metformin has an antimitogenic and proapoptotic effect in thyroid carcinoma cell lines and augments the antiproliferative effect of chemotherapeutic agents, such as doxorubicin and cisplatin.
Furthermore, it was found to inhibit insulin-induced growth stimulation via interference with the insulin/IGF signalling and the AMPK/mTOR pathway. 13 Similarly, treatment with metformin suppressed growth and metastatic potential in medullary thyroid carcinoma cells by down regulating the mTOR pathway.
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Limitations
Since, metformin suppresses pituitary TSH secretion as described above and also in previous studies, it would be difficult to evaluate whether LT4 supplementation is adequate or not for hypothyroid patients using metformin.
Conclusion
The results of this study showed that treatment with metformin is associated with a significant reduction (at three months, six months and 12 months respectively) in the serum levels of TSH in primary hypothyroidism patients on stable and adequate levothyroxine (LT4) doses and found to have diabetes or prediabetes. TSH reduction is not associated with reciprocal changes in FT4 at three months but at six months and 12 months TSH reduction is associated with significant increase of FT4 level.
